|
Sign In to gain access to subscriptions and/or personal tools.
|
The Tg.AC (v-Ha-ras) Transgenic Mouse: Nature of the Model
Raymond W. Tennant
National Institute of Environmental Health Sciences, Laboratory of Environmental Carcinogenesis and Mutagenesis, Research Triangle Park, North Carolina 27709, tennant{at}niehs.nih.gov
Stanley Stasiewicz
National Institute of Environmental Health Sciences, Laboratory of Environmental Carcinogenesis and Mutagenesis, Research Triangle Park, North Carolina 27709
William C. Eastin
National Institute of Environmental Health Sciences, Environmental Toxicology Program, Research Triangle Park, North Carolina 27709
John H. Mennear
103 Eagle Court, P.O. Box 5032, Cary, North Carolina 27511
Judson W. Spalding
National Institute of Environmental Health Sciences, Laboratory of Environmental Carcinogenesis and Mutagenesis, Research Triangle Park, North Carolina 27709
The Tg.AC (v-Ha-ras) transgenic mouse model provides a reporter phenotype of skin papillomas in response to either genotoxic or nongenotoxic carcinogens. In common with the conventional bioassay, the Tg.AC model responds to known human carcinogens and does not respond to noncarcinogens. It also does not respond to most chemicals that are positive in conventional bioassays principally at sites of high spontaneous tumor incidence. The mechanism of response of the Tg.AC model is related to the structure and genomic position of the transgene and the induction of transgene expression through specific mediated interactions between the chemicals and target cells in the skin.
Key Words: Chemical carcinogens • alternative carcinogen bioassay • ras gene • transgenic mouse.
References
- Ashby J., Tennant RW (1991). Defi nitive relationships among chemical structure, carcinogenicity and mutagenicity for 301 chemicals tested by the U.S. NTP. Mut Res 257: 229—306.[Web of Science][Medline]
[Order article via Infotrieve]
- Blanchard KT, Ball DJ, Holden HE, Furst SM, Stoltz JH, Stoll RE (1998). Dermal carcinogenicity in transgenic mice: Relative responsiveness of male and female hemizygous and homozygous Tg.AC mice to 12-0-tetradecanoylphorbol 13-acetate (TPA) and benzene. Toxicol Pathol 26: 541—547.[Abstract/Free Full Text]
- Bos JL (1998). All in the family? New insights and questions regarding interconnectivity of Ras, Rap1, and Ral. EMBO J 17: 6776—6782.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Cannon RE, Spalding JW, Trempus CS, Szczesniak CJ, Virgil KM, Humble MC, Tennant RW (1997). Kinetics of wound-induced v-Ha-ras transgene expression and papilloma development in transgenic Tg.AC mice. Mol Carcinog 20: 108—114.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- CannonRE, Graves S., Spalding JW, Trempus CS, TennantRW (2000). Oral administration of dimethylvinyl chloride increases frequency of forestomach papillomas in Tg.AC mice. Mol Carcinog 29: 229—235.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Dunson D., Haseman J., vanBirgelen A., Stasiewicz S., Tennant RW (2000). Statistical analysis of skintumor data fromTg.AC mousebioassays. Toxicol Sci 55: 293—302.[Abstract/Free Full Text]
- Eastin W., Haseman J., Mahler J., Bucher J. (1998). The National Toxicology Program evaluation of genetically altered mice as predictive models for identifying carcinogens. Toxicol Pathol 26: 461—473.[Abstract/Free Full Text]
- Germolec DR, Spalding J., Yu HS, Chen GS, Simeonova PP, Humble MC, Bruccoleri A., Boorman GA, Foley JF, YoshidaT., Luster MI (1998). Arsenic enhancement of skin neoplasia by chronic stimulation of growth factors. Am J Pathol 153:1775—1785.[Abstract/Free Full Text]
- Goelz MF, Mahler J., Harry J., Myers P., Clark J., Thigpen JE, Forsythe DB (1998). Neuropathologic fi ndings associated with seizures in FVB mice. Lab Anim Sci 48: 34—37.[Web of Science][Medline]
[Order article via Infotrieve]
- Hansen LA, Trempus CS, Mahler JF, Tennant RW (1996). Association of tumor development with increased cellular proliferation and transgene over-expression but not c-Ha-ras mutations, in v-Ha-ras transgenic Tg.AC mice. Carcinogenesis 17: 1825—1833.[Abstract/Free Full Text]
- Haseman JK, Hailey, JR, Morris RW (1998). Spontaneous neoplasm incidences in Fischer 344 rats and B6C3F1 mice in two-year carcinogenicity studies: A National Toxicology Program update. Toxicol Pathol 26: 428— 441.[Abstract/Free Full Text]
- Holden H., Stoll R., Spalding J., Tennant R. (1998). Hemizygous Tg.AC transgenic mouse as a potential alternative to the two-year mouse carcinogenicity bioassay: Evaluation of husbandry and housing factors. J of Appl Toxicol 18: 19—24.[CrossRef]
- Humble MC, Kouprina N., Noskov VN, Graves J., Garner E., Tennant RW, Resnick MA, Larionov V., Cannon RE (2000). Radial transformation-associated recombination cloning from the mouse genome: Isolation of Tg.AC transgene with fl anking DNAs. Genomics 70: 292—299.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Leder A., Kuo A., Cardiff R., Sinn E., Leder P. (1990). v-Ha-ras transgene abrogates the initiation step in mouse skintumorigenesis: Effects of phorbol esters and retinoic acid. Proc Natl Acad Sci USA 87: 9178—9182.[Abstract/Free Full Text]
- Mahler JF, Stokes W., Mann PC, Takaoka M., Maronpot RR (1996). Spontaneous lesions in aging FVB/N mice. Toxicol Pathol 24: 710— 716.
- Mahler J., Flagler N., Malarkey D., Mann P., Haseman J., Eastin W. (1998). Spontaneous and chemically induced proliferative lesions in Tg.AC transgenic and p53-heterozygous mice. Toxicol Pathol 26: 501—511.[Abstract/Free Full Text]
- Maronpot RR, Fox T., Malarkey DE, Goldsworthy T. (1995). Mutations in the ras proto-oncogene: Clues to etiology and molecular pathogenesis of mouse liver tumors. Toxicology 101: 125—156.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- NTP (1990). Toxicology and carcinogenesis studies of glycidol (CAS No. 556-52-5) in F344/N rats and B6C3F 1 mice (gavage studies). National Toxicology Program, Research Triangle Park, North Carolina. Technical Report No. 374.
- Robinson D. (1998). The International Life Sciences Institute's role in the evaluation of alternative methodologies for the assessment of carcinogenic risk. Toxicol Pathol 26: 474—475.[Free Full Text]
- Sanders JM, BurkaLT, Chanas B., Matthews HB (2001). Comparative xenobiotic metabolism between Tg.AC and p53 +/- genetically altered mice and the respective wildtypes. Toxicol Sci (in press).
- Slaga TJ, Fischer SM (1983). Strain differences and solventeffects in mouse skin carcinogenesis experiments using carcinogens, tumor initiators and promoters. Prog Exp Tumor Res 26: 85—109.[Web of Science][Medline]
[Order article via Infotrieve]
- Spalding JW, Momma J., Elwell MR, Tennant RW (1993). Chemically induced skin carcinogenesis in a transgenic mouse line (Tg.AC) carrying a v-Ha-ras gene. Carcinogenesis 14: 1335—1341.[Abstract/Free Full Text]
- Spalding JW, French JE, Tice RR, Furedi-Machacek M., Haseman JK, Tennant RW (1999). Development of a transgenic mouse model for carcinogenesis bioassays: Evaluation of chemically induced skin tumors in Tg.AC mice. Toxicol Sci 49: 241—254.[Abstract/Free Full Text]
- Spalding J., French J., Stasiewicz S., Furedi-Machacek M., Conner F., Tice R., Tennant R. (2000). Responses of transgenic mouse lines p53(defi cient) and Tg.AC to agents tested in conventional carcinogenicity bioassays. Toxicol Sci53:213—223.[Abstract/Free Full Text]
- TennantRW, French JE, Spalding JW (1995). Identifying chemical carcinogens and assessing potential risk in short-term bioassays using transgenic mouse models. Environ Health Perspect 103: 942—950.[Web of Science][Medline]
[Order article via Infotrieve]
- Tennant RW, Stasiewicz S., Mennear J., French JE, Spalding JW (1999). Genetically altered mouse models for identifying carcinogens. In: The Use of Short- and Medium-term Tests for Carcinogens and Data on Genetic and Related Effects in Carcinogenic Hazard Evaluation, McGregor D, Rice J, Venitt S (eds). IARC, Lyon, France, pp 123—150.
- Thompson K., Rosenzweig B., Sistare F. (1998). An evaluation of the hemizygous transgenic Tg.AC mouse for carcinogenicity testing of pharmaceuticals. II. A genotypic marker that predicts tumorigenic responsiveness. Toxicol Pathol 26: 548—555.[Abstract/Free Full Text]
- Trempus C., Mahler J., Ananthaswamy H., Loughlin S., Tennant R., French J. (1998). Photocarcinogenesis and susceptibility to UV radiation in the v-Ha-ras transgenic Tg.AC mouse. J Invest Dermatol 111: 445—451.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Van Duuren BL, Langseth L., Goldschmidt BM, Orris L. (1967). Carcinogenicity of epoxides, lactones, and peroxy compounds. VI. Structure and carcinogenic activity. J Nat Cancer Inst 39: 1217—1228.[Web of Science][Medline]
[Order article via Infotrieve]
- Vainio H., Wilbourn J. (1993). Cancer etiology: Agents causally associated with human cancer. Pharmacol and Toxicol 72: Supplement 1, S4—S11.[Web of Science]
- Weaver J., Contrera J., Rosenzweig B., Thompson K., Faustino P., Strong J., Ellison C., Anderson L., Prasanna H., Long-Bradley P., Lin K., Zhang J., Sistare F. (1998). An evaluation of the hemizygous transgenic Tg.AC mouse for carcinogenicity testing of pharmaceuticals. I. Evidence for a confounding nonresponder phenotype. Toxicol Pathol 26: 532—540.[Abstract/Free Full Text]
- Wright J., Hansen L., Mahler J., Szczesniak C., Spalding J. (1995). Odontogenic tumors in the v-Ha-ras (Tg.AC) transgenic mouse. Arch Oral Biol 40: 631—638.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
Toxicologic Pathology, Vol. 29, No. 1 suppl,
51-59 (2001)
DOI: 10.1080/019262301753178474
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
M. J. Jonker, O. Bruning, M. van Iterson, M. M. Schaap, T. V. van der Hoeven, H. Vrieling, R. B. Beems, A. de Vries, H. van Steeg, T. M. Breit, et al.
Finding transcriptomics biomarkers for in vivo identification of (non-)genotoxic carcinogens using wild-type and Xpa/p53 mutant mouse models
Carcinogenesis,
October 1, 2009;
30(10):
1805 - 1812.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Doi, J. R. Hailey, M. Hejtmancik, J. D. Toft II, M. Vallant, and R. S. Chhabra
Topical Application of Representative Multifunctional Acrylates Produced Proliferative and Inflammatory Lesions in F344/N Rats and B6C3F1 Mice, and Squamous Cell Neoplasms in Tg.AC Mice
Toxicol Pathol,
October 1, 2005;
33(6):
631 - 640.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Santostefano, D. J. Hoivik, and R. T. Miller
Investigations of Clofibrate in Alternative Carcinogenicity Models
International Journal of Toxicology,
September 1, 2005;
24(5):
285 - 288.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Nesfield, C. J. Clarke, D. J. Hoivik, R. T. Miller, J. S. Allen, K. Selinger, and M. J. Santostefano
Evaluation of the Carcinogenic Potential of Clofibrate in the rasH2 Mouse
International Journal of Toxicology,
September 1, 2005;
24(5):
301 - 311.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. E. Torrey, H. G. Wall, J. A. Campbell, P. Kwanyuen, D. J. Hoivik, R. T. Miller, J. S. Allen, M. J. Jayo, K. Selinger, P. M. Savina, et al.
Evaluation of the Carcinogenic Potential of Clofibrate in FVB/Tg.AC Mouse After Oral Administration--Part I
International Journal of Toxicology,
September 1, 2005;
24(5):
313 - 325.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. E. Torrey, H. G. Wall, J. A. Campbell, P. Kwanyuen, D. J. Hoivik, R. T. Miller, J. S. Allen, M. J. Jayo, K. Selinger, and M. J. Santostefano
Evaluation of the Carcinogenic Potential of Clofibrate in the FVB/Tg.AC Mouse After Dermal Application--Part II
International Journal of Toxicology,
September 1, 2005;
24(5):
327 - 339.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Payne and C. J. Kemp
p27 Kip1 (Cdkn1b)-Deficient Mice Are Susceptible to Chemical Carcinogenesis and May Be a Useful Model for Carcinogen Screening
Toxicol Pathol,
June 1, 2003;
31(4):
355 - 363.
[Abstract]
[PDF]
|
|
|
|
|
|
|
Committee on Carcinogenicity of Chemicals in Food, Consumer Products and the Environment Statement on ILSI/HESI Research Programme on Alternative Cancer Models
Toxicol Pathol,
February 1, 2003;
31(2):
254 - 257.
[PDF]
|
|
|
|
|
|
|
F. D. Sistare, K. L. Thompson, R. Honchel, and J. DeGeorge
Evaluation of the Tg.AC Transgenic Mouse Assay for Testing the Human Carcinogenic Potential of Pharmaceuticals--Practical Pointers, Mechanistic Clues, and New Questions
International Journal of Toxicology,
January 1, 2002;
21(1):
65 - 79.
[Abstract]
[PDF]
|
|
|
|
|
